pentobarbital will reduce the level or outcome of diazepam buccal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch. Robust or reasonable CYP3A4 inducers may perhaps enhance charge of diazepam elimination; hence, efficacy of diazepam may very well be decreased.
Drugs that have stage therapy related with Just about every prescription. This restriction normally requires that specific requirements be met just before approval for the prescription.
Observe Intently (one)pentobarbital will lessen the level or effect of levamlodipine by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will lower the level or impact of clozapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
pentobarbital will minimize the extent or impact of isradipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unknown.
Contraindicated. Coadministration of doravirine with a strong CYP3A inducer may well decrease doravirine plasma concentrations and/or effects. Opportunity for loss of virologic reaction and feasible resistance to doravirine.
pentobarbital will decrease the extent or influence of pimozide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Unidentified.
pentobarbital will minimize the level or impact of montelukast by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unknown.
pentobarbital will lessen the level or influence of stiripentol by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Stay clear of or Use Alternate Drug. If unable to avoid coadministration of stiripentol with strong CYP3A4 inducers, maximize stiripentol dose.
pentobarbital will lessen the extent or outcome of mavacamten by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
pentobarbital will reduce the level or impact of duvelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Prevent or Use Alternate Drug. Coadministration with read more a solid CYP3A inducer decreases duvelisib space underneath the curve (AUC), which may minimize duvelisib efficacy.
If unable to stay away from, double current pralsetinib dose starting up on Day 7 of coadministration with robust CYP3A inducer. Immediately after inducer has been discontinued for at least fourteen times, resume previous pralsetinib dose.
With therapeutic doses of TCAs, barbiturates raise metabolism and reduce blood concentrations of TCAs.
pentobarbital will decrease the level or result of sulfamethoxazole by impacting hepatic enzyme CYP2C9/10 metabolism. Minimal/Importance Unknown.